Objective: To establish a HPLC-MS/MS method for the determination of vitexin in rat plasma and its pharmacokinetics.
Methods: The HPLC-MS/MS method used Capcell Pak C18 column (50 mm x 2.0 mm I. D., 5 microm). The mobile phase was methanol and water (95:5, V/V, containing 0.1% formic acid) at a flow rate of 0.2 mL/min. Electrospray ionization (ESI) in negative ion mode and multiple reaction monitoring (MRM) was used for the quantification of vitexin with a monitored transitions m/z 431-->311 for vitexin and m/z 269-->225 for internal standard (I. S., emodin).
Results: Linear calibration curves were obtained over the concentration range of 0.5-2000 ng/mL (r = 0.9960) with the lowest limit of quantification (LLOQ) of 0.5 ng/mL. The recovery was in the range of 76.1%-89.0%. The relative standard deviations for the intra-day and inter-day validation were less than 11%.
Conclusion: The method is simple, accurate, fast, sensitive and suitable for the pharmacokinetic study of vitexin in rats.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Facile synthesis of hierarchically flower-like hollow covalent organic frameworks for enrichment and metabolic analysis of benzophenone derivatives in mouse serum.
J Chromatogr A
January 2025
Ministry of Education Key Laboratory of Analytical Science for Food Safety and Biology, Fujian Provincial Key Laboratory of Analysis and Detection Technology for Food Safety, College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350108, China. Electronic address:
Benzophenone derivatives (BPs), as synthetic chemicals widely used in personal care products, have drawn increasing attention due to their potential health risks. However, monitoring BPs in biological samples remains challenging due to their complex matrices and the deficiency in sensitivity and selectivity in current methods. Herein, a method combining hierarchically flower-like hollow covalent organic frameworks (HFH-COFs) with high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) was established for the enrichment and detection of BPs in serum samples.
View Article and Find Full Text PDFMetabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies.
Neuro Oncol
January 2025
MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
Background: Our group and others have recently identified four molecular groups of meningioma, with unique underlying biology and outcomes. The relevance of group-specific metabolite profiles (particularly among hypermetabolic tumours), has not been explored.
Methods: We performed untargeted metabolic profiling of meningiomas representing each molecular group and WHO grade.
Pharmacokinetics of remimazolam, midazolam and diazepam in sheep.
Vet Anaesth Analg
December 2024
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA; Kenneth L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA.
Objective: To model pharmacokinetics of three benzodiazepines and their metabolites in sheep.
Study Design: A nonblinded, prospective, experimental study.
Animals: A group of six adult Hampshire-Suffolk cross-bred sheep (three females, three castrated males), 73 ± 3 kg (mean ± standard deviation).
Method for Testing Drugs Belonging to Substrates and Inhibitors of the Transporter Protein BCRP on CACO-2 Cells.
Dokl Biochem Biophys
January 2025
Ryazan State Medical University, Ryazan, Russian Federation.
Introduction: Breast cancer resistance protein (BCRP) is an efflux membrane transporter that controls the pharmacokinetics of a large number of drugs. Its activity may change when taking some endo- and exogenous substances, thus making it a link in drug interactions.
Aim: The aim of the study was to develop a methodology for testing drugs for belonging to BCRP substrates and inhibitors in vitro.
Challenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review.
Antibodies (Basel)
January 2025
Federal Institute of Material Testing and Research (BAM), 12489 Berlin, Germany.
This review describes mass spectrometry (MS)-based approaches for the absolute quantification of therapeutic monoclonal antibodies (mAbs), focusing on technical challenges in sample treatment and calibration. Therapeutic mAbs are crucial for treating cancer and inflammatory, infectious, and autoimmune diseases. We trace their development from hybridoma technology and the first murine mAbs in 1975 to today's chimeric and fully human mAbs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!